dimethyl fumarate newbury 240 mg enterokapsel, hård
newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne
dimethyl fumarate newbury 120 mg enterokapsel, hård
newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 120 mg - dimetylfumarat 120 mg aktiv substans; propylenglykol hjälpämne
dimethyl fumarate sandoz 120 mg enterokapsel, hård
sandoz a/s - dimetylfumarat - enterokapsel, hård - 120 mg - propylenglykol hjälpämne; dimetylfumarat 120 mg aktiv substans
dimethyl fumarate sandoz 240 mg enterokapsel, hård
sandoz a/s - dimetylfumarat - enterokapsel, hård - 240 mg - propylenglykol hjälpämne; dimetylfumarat 240 mg aktiv substans
dimetylfumarat avansor 240 mg enterokapsel, hård
avansor pharma oy - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne
dimetylfumarat avansor 120 mg enterokapsel, hård
avansor pharma oy - dimetylfumarat - enterokapsel, hård - 120 mg - propylenglykol hjälpämne; dimetylfumarat 120 mg aktiv substans
dimethyl fumarate glenmark 240 mg enterokapsel, hård
glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hård - 240 mg - natriumlaurilsulfat hjälpämne; natriumbensoat hjälpämne; propylenglykol hjälpämne; cetostearylalkohol hjälpämne; dimetylfumarat 240 mg aktiv substans
dimethyl fumarate glenmark 120 mg enterokapsel, hård
glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hård - 120 mg - dimetylfumarat 120 mg aktiv substans; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne; natriumbensoat hjälpämne; cetostearylalkohol hjälpämne
tysabri
biogen netherlands b.v. - natalizumab - multipel skleros - selektiva immunsuppressiva medel - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multipel skleros, skovvis förlöpande - immunsuppressiva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).